Vantage Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Vantage Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$4K	Hold	200	–	–	﹤0.01%	660
2018 Q2	$5K	Hold	200	–	–	﹤0.01%	638
2018 Q1	$3K	Hold	200	–	–	﹤0.01%	712
2017 Q4	$4K	Hold	200	–	–	﹤0.01%	705
2017 Q3	$4K	Sell	200 -340	-63%	-$7.65K	﹤0.01%	689
2017 Q2	$18K	Sell	540 -125	-19%	-$3.87K	0.01%	444
2017 Q1	$21K	Hold	665	–	–	0.01%	397
2016 Q4	$24K	Hold	665	–	–	0.01%	371
2016 Q3	$31K	Sell	665 -28	-4%	-$1.46K	0.01%	316
2016 Q2	$35K	Buy	693 +78	+13%	+$4.15K	0.01%	313
2016 Q1	$33K	Buy	615 +75	+14%	+$4.4K	0.01%	308
2015 Q4	$35K	Buy	540 +340	+170%	+$21K	0.02%	288
2015 Q3	$11K	Hold	200	–	–	0.01%	481
2015 Q2	$12K	Sell	200 -200	-50%	-$12.3K	0.01%	449
2015 Q1	$25K	Buy	400 +200	+100%	+$11.6K	0.01%	451
2014 Q4	$12K	Hold	200	–	–	0.01%	470
2014 Q3	$11K	Hold	200	–	–	0.01%	469
2014 Q2	$10K	Hold	200	–	–	0.01%	474
2014 Q1	$11K	Hold	200	–	–	0.01%	423
2013 Q4	$8K	Buy	+200	New	+$7.88K	0.01%	432

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Vantage Investment Advisors's TEVA Position: Q3 2018 in Review

Vantage Investment Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q3 2018 at 200 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #660.

Vantage Investment Advisors first reported a position in TEVA in Q4 2013 and has held it in 20 quarters since. The position peaked at $35K in Q2 2016. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

Vantage Investment Advisors held 200 shares of Teva Pharmaceuticals worth $4K as of Q3 2018.
Vantage Investment Advisors left its Teva Pharmaceuticals share count unchanged in Q3 2018.
Teva Pharmaceuticals made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #660 holding.
Vantage Investment Advisors first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 20 quarters since.
Vantage Investment Advisors's Teva Pharmaceuticals position peaked at $35K in Q2 2016.
556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.